<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04439409</url>
  </required_header>
  <id_info>
    <org_study_id>19CH103</org_study_id>
    <secondary_id>2019-A01343-54</secondary_id>
    <nct_id>NCT04439409</nct_id>
  </id_info>
  <brief_title>Variability of the Autonomic Nervous System (ANS) During Cluster Headache (CH).</brief_title>
  <acronym>AVASNA</acronym>
  <official_title>AVASNA : Variability of the Autonomic Nervous System (ANS) During Cluster Headache (CH).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cluster Headache (CH) is associated with ipsilateral vegetative signs, related to&#xD;
      parasympathetic system hyperactivity and/or signs of sympathetic hypoactivity. The precise&#xD;
      mechanism of Cluster Headache (CH) is still unknown. The question is whether these&#xD;
      dysautonomic disorders are simply secondary to the Cluster Headache (CH) process or whether&#xD;
      they are the triggering factor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study cares about the evolution of the Autonomic Nervous System (ANS) in Cluster&#xD;
      Headache (CH) seizures. Patients will be offered Holter ECG to study the temporal&#xD;
      relationships between changes in Autonomic Nervous System (ANS) activity during Headache (CH)&#xD;
      seizures and changes in Autonomic Nervous System (ANS) activity before and after seizure&#xD;
      treatment, using heart rate variability measurement.&#xD;
&#xD;
      The hypothesis is that there would be an initial temporary sympathetic activation, followed&#xD;
      quickly by parasympathetic hyperactivation and a return to a state of equilibrium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Low Frequency/High Frequency (LF/HF) ratio at the onset of the first night seizure</measure>
    <time_frame>Day: 7</time_frame>
    <description>Comparison of the Low Frequency/High Frequency (LF/HF) ratio at the onset of the first night seizure during the basal period, pre-seizure, seizure and after the seizure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low Frequency/High Frequency (LF/HF) ratio at the onset of the first daytime seizure</measure>
    <time_frame>Day: 7</time_frame>
    <description>Comparison of the Low Frequency/High Frequency (LF/HF) ratio at the onset of the first daytime seizure during the basal period, pre-seizure, seizure and after the seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Frequency during daytime and night seizure</measure>
    <time_frame>Day: 7</time_frame>
    <description>Comparison of measure of Low Frequency during daytime and night seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Frequency (HF) during daytime and night seizure</measure>
    <time_frame>Day: 7</time_frame>
    <description>Comparison of measure of High Frequency (HF) during daytime and night seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between several parameters</measure>
    <time_frame>Day: 7</time_frame>
    <description>Correlation between Heart Rate Variability (HRV), changes in the Low Frequency/High Frequency (LF/HF) ratio, the Low Frequency (LF) and the High Frequency (HF), and the intensity of pain measured on the Visual Analog Scale (VAS).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Patients with Cluster Headache (CH)</arm_group_label>
    <description>Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holter electrocardiogram</intervention_name>
    <description>Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.</description>
    <arm_group_label>Patients with Cluster Headache (CH)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Cluster Headache (CH) will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years of age&#xD;
&#xD;
          -  Affiliated or entitled to a Social Security scheme&#xD;
&#xD;
          -  Resident in the territories of the hospital grouping of Loire territory (located less&#xD;
             than 50 km away)&#xD;
&#xD;
          -  Whose diagnosis of episodic or chronic Cluster Headache (CH) has been confirmed&#xD;
             according to International Classification of Headache Disorders (ICHD)- 3 criteria&#xD;
&#xD;
          -  With a regular sinus rhythm and heart rate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Conditions contraindicating the use of injectable sumatriptan&#xD;
&#xD;
          -  Conditions likely to affect the Autonomic Nervous System (ANS): dysautonomic sensory&#xD;
             neuropathies, sleep apnea syndrome, etc.&#xD;
&#xD;
          -  Cognitive or language disorders that may interfere with pain assessment and seizure&#xD;
             follow-up.&#xD;
&#xD;
          -  Patients taking treatments that may modify the Autonomic Nervous System (ANS):&#xD;
             catecholamine (adrenaline, noradrenaline, dopamine), B-stimulants (isoprenaline,&#xD;
             dobutamine, dopexamine, salbutamol, terbutaline, fenoterol, orciprenaline,&#xD;
             clenbuterol, salmeterol, formoterol), B-blockers, alpha-stimulants (midodrine,&#xD;
             alpha-methyl-dopa, clonidine, rilmenidine, moxonidine), alpha-blockers (phentolamine,&#xD;
             prazosin, urapidil), amphetamine, tyramine, ephedrine, selegiline, cocaine,&#xD;
             imipramine.&#xD;
&#xD;
          -  Impossibility to submit to the medical follow-up of the program for geographical,&#xD;
             social or psychological reasons.&#xD;
&#xD;
          -  Patient deprived of liberty or under guardianship.&#xD;
&#xD;
          -  Patient with preventive background treatment of Cluster Headache (CH).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle CREAC'H, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christelle CREAC'H, MD</last_name>
    <phone>(0)4.77.12.76.48</phone>
    <phone_ext>+33</phone_ext>
    <email>christelle.creach@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fleur PETIT, CRA</last_name>
    <phone>(0)4.77.82.95.58</phone>
    <phone_ext>+33</phone_ext>
    <email>Fleur.Petit@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christelle CREAC'H, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland PEYRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malou NAVEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice LIETAR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Claude BARTHELEMY, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric ROCHE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David CHARIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cluster Headache</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <keyword>Seizure</keyword>
  <keyword>Holter</keyword>
  <keyword>Electrocardiogram</keyword>
  <keyword>(LF/HF) ratio</keyword>
  <keyword>Daytime seizure</keyword>
  <keyword>Night seizure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

